Don't Judge Moderna on Technicals Alone - Check Its Fundamentals!

By Susan Ramirez • Monday, December 18 12:28 • Permanent Link

Moderna logged a -1.5% change during today's afternoon session, and is now trading at a price of $84.7 per share. The S&P 500 index moved 1.0%. MRNA's trading volume is 2,163,086 compared to the stock's average volume of 4,444,758.

Moderna trades -28.67% away from its average analyst target price of $118.74 per share. The 19 analysts following the stock have set target prices ranging from $47.67 to $275.01, and on average have given Moderna a rating of hold.

If you are considering an investment in MRNA, you'll want to know the following:

Moderna has moved -54.7% over the last year, and the S&P 500 logged a change of 23.6%
Based on its trailing earnings per share of -9.23, Moderna has a trailing 12 month Price to Earnings (P/E) ratio of -9.2 while the S&P 500 average is 15.97
MRNA has a forward P/E ratio of -13.7 based on its forward 12 month price to earnings (EPS) of $-6.18 per share
The company has a price to earnings growth (PEG) ratio of 0.14 — a number near or below 1 signifying that Moderna is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.4 compared to its sector average of 4.08
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Based in Cambridge, the company has 3,900 full time employees and a market cap of $32.29 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.